Promising targeted therapies for gliomas with the BRAF V600E mutation include BRAF inhibitors such as Vemurafenib and Dabrafenib, as well as combinations of BRAF and MEK inhibitors [53]. This evidence concerns the gene BRAF and central nervous system cancer.